Geode Capital Management
VRCA icon

Geode Capital Management’s Verrica Pharmaceuticals VRCA Stock Holding History

Geode Capital Management’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$735K Buy
138,917
+71,258
+105% +$456K ﹤0.01% 3455
2025
Q4 		$562K Hold
67,659
– – ﹤0.01% 3547
2025
Q3 		$292K Buy
67,659
+3,043
+5% +$18.4K ﹤0.01% 3806
2025
Q2 		$343K Sell
64,616
-37,233
-37% -$200K ﹤0.01% 3675
2025
Q1 		$450K Buy
101,849
+54,122
+113% +$350K ﹤0.01% 3581
2024
Q4 		$334K Buy
47,727
+2,179
+5% +$23.9K ﹤0.01% 3727
2024
Q3 		$661K Sell
45,548
-788
-2% -$35.5K ﹤0.01% 3499
2024
Q2 		$3.38M Buy
46,336
+1,405
+3% +$108K ﹤0.01% 2930
2024
Q1 		$2.66M Buy
44,931
+1,963
+5% +$108K ﹤0.01% 3005
2023
Q4 		$3.15M Buy
42,968
+1,289
+3% +$53K ﹤0.01% 2927
2023
Q3 		$1.62M Buy
41,679
+2,828
+7% +$144K ﹤0.01% 3145
2023
Q2 		$2.24M Buy
38,851
+20,763
+115% +$1.26M ﹤0.01% 3075
2023
Q1 		$1.18M Buy
18,088
+1,792
+11% +$108K ﹤0.01% 3270
2022
Q4 		$448K Buy
16,296
+1,272
+8% +$33.9K ﹤0.01% 3707
2022
Q3 		$438K Buy
15,024
+2,910
+24% +$99.7K ﹤0.01% 3787
2022
Q2 		$232K Sell
12,114
-9,626
-44% -$484K ﹤0.01% 4173
2022
Q1 		$1.76M Sell
21,740
-43
-0.2% -$3.54K ﹤0.01% 3313
2021
Q4 		$2M Sell
21,783
-2,024
-9% -$229K ﹤0.01% 3358
2021
Q3 		$2.98M Buy
23,807
+2,509
+12% +$281K ﹤0.01% 3185
2021
Q2 		$2.41M Buy
21,298
+1,382
+7% +$167K ﹤0.01% 3209
2021
Q1 		$3.02M Buy
19,916
+1,439
+8% +$199K ﹤0.01% 3049
2020
Q4 		$2.13M Sell
18,477
-155
-0.8% -$14.2K ﹤0.01% 3051
2020
Q3 		$1.44M Sell
18,632
-1,120
-6% -$91.7K ﹤0.01% 3056
2020
Q2 		$2.17M Buy
19,752
+1,745
+10% +$202K ﹤0.01% 2793
2020
Q1 		$1.97M Buy
18,007
+1,683
+10% +$221K ﹤0.01% 2682
2019
Q4 		$2.59M Buy
16,324
+1,951
+14% +$288K ﹤0.01% 2847
2019
Q3 		$2.12M Buy
14,373
+6,181
+75% +$689K ﹤0.01% 2910
2019
Q2 		$951K Buy
8,192
+2,034
+33% +$191K ﹤0.01% 3255
2019
Q1 		$665K Buy
6,158
+2,467
+67% +$285K ﹤0.01% 3317
2018
Q4 		$300K Buy
3,691
+889
+32% +$108K ﹤0.01% 3557
2018
Q3 		$455K Buy
+2,802
New +$479K ﹤0.01% 3496

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Geode Capital Management's VRCA Position: Q1 2026 in Review

Geode Capital Management increased its Verrica Pharmaceuticals (VRCA) stake by 105% in Q1 2026, buying an estimated $456K and bringing the position to 138,917 shares worth $735K. The position accounts for ﹤0.01% of the portfolio, ranked #3455.

Geode Capital Management first reported a position in VRCA in Q3 2018 and has held it in 31 quarters since. The position peaked at $3.38M in Q2 2024. 39 funds tracked by Wall St. Rank hold VRCA as of Q1 2026.

  • Geode Capital Management held 138,917 shares of Verrica Pharmaceuticals worth $735K as of Q1 2026.
  • Geode Capital Management bought 71,258 Verrica Pharmaceuticals shares in Q1 2026, an estimated $456K.
  • Verrica Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3455 holding.
  • Geode Capital Management first reported a position in Verrica Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • Geode Capital Management's Verrica Pharmaceuticals position peaked at $3.38M in Q2 2024.
  • 39 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.